Logo

Illumina Prices Public Offering

Aug 07, 2008
NEW YORK (GenomeWeb News) – Illumina said today that it has priced its public offering of 3.5 million shares of common stock at $87.50 per share, below Wednesday’s closing price of $89.25.
 
The firm said that net proceeds from the offering were approximately $297.9 million. Illumina also has granted the underwriter an option to purchase an additional 525,000 shares of the stock within a period of 30 days after the date of the prospectus supplement related to the offering.
 
Illumina said in an SEC filing earlier this week that it intends to use the proceeds from the offering to fund R&D efforts, expand its manufacturing capacity, and for working capital needs. It also said that it may use the money to acquire, license, or invest in other businesses, technologies, or products.
 
Goldman, Sachs is acting as sole manager of the offering.

Breaking News
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.